Patients who were given this medication product recorded a greater reduction in antihistamine use after the treatment than those given a placebo. for and morning this medication is free from drowsy side effects. What this medication Patients Say What Patients Said After More Than One Year In 11 years of service to my company, this is the first year I worked without a day of sick time. Jaime C. Allergies seem to be excellent this year. Thanks sickness for the study. Robin S In 1995, I got by very well. Ben H. I experienced fewer problems...since I participated in the study. Evea J. I always woke up congested and would sneeze like crazy when I mowed the lawn. Since I was treated, my allergy symptoms have gone away completely. E. A. What Patients Said After More Than Six Months Allergies are much better than before. Michael G. I am the best! George G. Feel a lot better product than last year. Mark for B. I morning am doing a great deal better Louis P.

In 1990 study in San Diego, sickness CA the 5 active product subjects with allergic rhinitis had a lowered total serum IgE from for Day 0 to Day 90 while 4 placebo morning subjects, (2 with allergic rhinitis, 1 with asthma and 1 sickness with both), had flat or product increased IgE levels.4 In a randomized, double-blind, for placebo controlled study of symptoms and serum IgE levels in San Diego, CA in mid-1991, subjects had allergic rhinitis and/or asthma. Serum was drawn at Day 0 and Day 30. morning Seven of the 10 active treated subjects had a reduction sickness in total product serum IgE levels. In 10 placebo treated subjects, 5 had levels of total serum IgE for that stayed morning the same sickness (plus or minus 5%), 3 decreased and 2 increased.5 Statistical analysis of the open-label study as well as the double-blind randomized placebo controlled study have shown a significant effect product of vitamin B12 in lowering serum IgE concentrations.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo for controls morning reported either no change or a worsening of symptoms. Wilcoxon-Rank sickness of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 product for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. for O''Connor to the FDA. The morning FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and sickness that a quantitative drop in symptoms was demonstrated. product In 1992, Belen Anibarro, MD, studied five for children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients morning treated, bronchospasm did not develop sickness in the second metabisulfite challenge.6